Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
A

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylating Agents Implemented Prior to Transplant Do Not Alter Transplant Outcomes

By Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Asmita Mishra
By Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Asmita Mishra
176 views
January 28, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
06:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML U…

Feat. S. Urrutia
10:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …

Feat. D. Tremblay
11:20
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021 Update on CMML Overview of the Most Recent Data

Feat. G. Montalban-Bravo
10:43
Naval Daver

MD Anderson Immune Checkpoint Based Approaches in AML & MDS: Whi…

15:33
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Oral HMAs in MDS: Can FDA-Approved Decitabine/C…

Feat. G. Garcia-Manero
12:19
University of Miami's 2nd Biennial Miami Leukemia Symposium

How to Calculate Risk in MDS Patients?

Feat. M. Sekeres
22:02
University of Miami's 2nd Biennial Miami Leukemia Symposium

TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decre…

Feat. A. Verma
14:59
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylatin…

Feat. R. Komrokji
21:24
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benef…

Feat. J. Tyner
11:18
Indy Hematology Review

Relapse After Allo HSCT - Treatment Strategies and Overview of Relat…

Feat. R. Childs
14:36
University of Miami's 2nd Biennial Miami Leukemia Symposium

Frontline Therapies in MDS: Leveling Lower-risk MDS

Feat. M. Sekeres
20:00
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

MDS/MPN Overlap Through Interactive Case Based Discussion: Overview …

Feat. A. Kuykendall
26:41
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on MDS: Luspatercept Under FDA Review, Novel Oral HM…

Feat. H. Carraway
06:53
Indy Hematology Review

Chronic Myelomonocytic Leukemia: Define, Diagnosis, Prognostications…

Feat. A. Tefferi
05:28
University of Miami's 2nd Biennial Miami Leukemia Symposium

Frontline Therapies in MDS: Hampering Higher-risk MDS

Feat. M. Sekeres
07:01
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of MDS: Clonal Hematopoiesis Increases Risk for Hema…

Feat. H. Carraway
19:25
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

MDS/MPN: Senectus Ipsa Est Morbus (Disease of Old Age)?

Feat. M. Deininger
20:06
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant…

Feat. T. Graubert
06:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML U…

Feat. S. Urrutia
10:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …

Feat. D. Tremblay